Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎, New York, NY 10065
(646) 856-9261
[email protected]

Naftali Bechar, M.D.

SVP of Clinical Development

Naftali Bechar is a medical oncologist with extensive expertise in oncology drug development and medical monitoring of oncology clinical trials. Naftali completed his training in internal medicine at New York University and in medical oncology at Memorial Sloan Kettering Cancer Center. He practiced medical oncology and served as a clinical investigator for 15 years, followed by a position as senior medical monitor at Covance, where he monitored early oncology trials with a focus on small molecule TKI and immune-oncology therapeutics in solid tumors. Following Covance, Naftali moved to PsiOxus, a biotech company specializing in oncolytic viruses, where he served as an executive medical director and later as interim CMO. After PsiOxus, Naftali moved to Astra Zeneca where he served as a study lead physician in two registration studies for a small molecule AKT inhibitor in prostate and breast cancer. Naftali is Inspirna’s Senior Vice President of Clinical Development.​